drugset / Trial / NCT02174211

A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.

NCT02174211

Non-randomizedParallel-groupOpen-labelTreatment

Summary

To study the effect of pars plana vitrectomy on the intravitreal pharmacokinetics of ranibizumab and to compare the half-life of ranibizumab and aflibercept.

Timeline

Start
2014-06
Primary completion
2020-11
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic Intravitreal
Comparator Ranibizumab Monoclonal antibody Intravitreal